Tiragolumab – Talk Bio

TIGIT Turmoil: How Pharma Burned Billions on Failed Immuno-Oncology Projects

4 weeks ago talkbio0Tagged Arcus Biosciences, Clinical Trials, Gilead, immuno-oncology, iTeos, Merck, Myers, Novartis, Pharma, Roche (company), SmithKline Beecham, squibb, TIGIT gene, Tiragolumab

TIGIT; immuno-oncology; failed clinical trials; pharma investment loss; Gilead; GSK; Bristol Myers Squibb; Novartis; Merck; Roche; iTeos; Arcus Biosciences; tiragolumab; belrestotug

Roche’s TIGIT Drug Candidate Tiragolumab Fails to Meet Overall Survival Endpoint in Phase 3 Lung Cancer Trial

8 months ago talkbio0Tagged Keytruda, Malignant neoplasm of lung, Overall Survival, Phase 3 trial, Roche (company), Skyscraper-01, Tecentriq, TIGIT gene, Tiragolumab

Roche, TIGIT, tiragolumab, lung cancer, phase 3 trial, SKYSCRAPER-01, overall survival, Keytruda, Tecentriq

Roche’s TIGIT Drug Tiragolumab Fails Another Phase 3 Lung Cancer Trial

1 year ago talkbio0Tagged Failure (biologic function), Keytruda, Malignant neoplasm of lung, Phase 3 trial, Roche (company), Tecentriq, TIGIT gene, Tiragolumab

Roche, TIGIT, tiragolumab, lung cancer, Phase 3 trial, failure, Keytruda, Tecentriq